View : 27 Download: 0
Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea
- Effect of lacidipine on blood pressure and endothelial function in mild-to-moderate essential hypertension patients with diabetes in Korea
- Kim D.-H.; Oh I.-Y.; Lee H.-Y.; Kim Y.-J.; Kim H.-S.; Kim C.-H.; Oh B.-H.; Kim K.-S.; Kim D.-I.; Kim Y.-D.; Ryu K.-H.; Park S.-H.; Baek S.-H.; Shin D.-G.; Shim W.J.; Ahn T.-H.; Oh S.-K.; Lee S.-H.; Lee S.-Y.; Jeong M.-H.; Chung W.-S.; Jeong J.-Y.; Choi S.-Y.; Choi S.-W.; Hyon M.-S.
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- Korean Circulation Journal
- vol. 40, no. 12, pp. 632 - 638
- SCIE; SCOPUS; KCI
- Background and Objectives: The aim of this study was to evaluate the efficacy of lacidipine in reducing blood pressure (BP) and to determine its effect on endothelial function in mild-to-moderate hypertensive patients with type 2 diabetes mellitus (DM). Subjects and Methods: This was a prospective, multicenter, open-label, single-arm study, enrolling 290 patients with mild-to-moderate hypertension and type 2 DM. Patients were initially treated with 2 mg lacidipine orally once daily for 4 weeks, which was then increased as necessary every 4 weeks to a maximal dose of 6 mg daily. The primary endpoint was the mean change in systolic blood pressure (SBP) from baseline after 12 weeks of treatment. Secondary endpoints included mean changes in diastolic blood pressure (DBP), flow-mediated vasodilatation (FMD), and serum concentrations of biochemical markers such as high-sensitivity C-reactive protein (hs-CRP), monocyte chemo-attractant protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), and plasminogen activator inhibitor-1 (PAI-1). Results: Lacidipine treatment significantly reduced SBP by -13.4±13.0 mmHg (p<0.001) and DBP by -6.2±9.3 mmHg (p<0.001). Lacidipine treatment did not improve endothelial-dependent vasodilatation, despite significantly improved nitroglycerin-induced, endothelial-independent vasodilatation. MCP-1 levels significantly decreased from 283.66±110.08 pg/mL to 257.83±100.23 pg/mL (p<0.001); whereas there were no significant changes in the levels of hs-CRP, MMP-9, or PAI-1. Conclusion: Twelve weeks of treatment with lacidipine was effective and well tolerated in mild-to-moderate hypertensive patients with type 2 DM. In spite of inducing a significant reduction in MCP-1 levels, lacidipine did not improve endothelial function. Copyright © 2010 The Korean Society of Cardiology.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.